


## (E/Z)-Elafibranor

Cat. No.:	HY-16737A
CAS No.:	824932-88-9
Molecular Formula:	C <sub>22</sub> H <sub>24</sub> O <sub>4</sub> S
Molecular Weight:	384.49
Target:	PPAR
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	(E/Z)-Elafibranor ((E/Z)-GFT505) is a PPAR $\alpha$ / $\delta$ agonist with EC <sub>50</sub> s of 45 and 175 nM, respectively <sup>[1][2][3]</sup> .
IC <sub>50</sub> & Target	EC50: 45 nM (PPAR- $\alpha$ ), 175 nM (PPAR- $\delta$ ) <sup>[1]</sup>

### REFERENCES

- [1]. Liu ZM, et al. Early investigational drugs targeting PPAR- $\alpha$  for the treatment of metabolic disease. *Expert Opin Investig Drugs*. 2015 May;24(5):611-21.
- [2]. Ratziu V, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- $\alpha$  and - $\delta$ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. *Gastroenterology*. 2016 May;150(5):1147-1159.
- [3]. Hanf R, et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects. *Diab Vasc Dis Res*. 2014 No

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA